Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab
Conclusion: Pseudo progression is only seen in a small part of patients treated with immunotherapy. With little tumor burden a treatment continuation can be feasible. Also patients who are not considered fit for second line chemotherapy may continue treatment. Aggressive tumor growth or high tumor load should stay a domain of conventional second line chemotherapy.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Rudiger, S., Kropf-Sanchen, C., Schmidtke-Schrezenmeier, G., Aksentiy, M., Hoss, K., Rottbauer, W. Tags: 11.1 Lung Cancer Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | CT Scan | Immunotherapy | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | PET Scan | Radiation Therapy | Respiratory Medicine